Get started
Work

Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study
DOI: 10.1158/1078-0432.22632965.v1
Authors: Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal, Sara A. Hayes, Andrew J. Plodkowski, Paul K. Paik, Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Franziska Michor, Helena A. Yu
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4365510495
Cites:
Cited by:
Related to: 10